News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xenon Pharmaceuticals Inc. Named Life Sciences Company of the Year by LifeSciences British Columbia


4/8/2013 10:02:21 AM

VANCOUVER, Canada, April 8, 2013 /PRNewswire/ -- Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award for 2013.

(Photo: http://photos.prnewswire.com/prnh/20130408/SF89970)

The LifeSciences British Columbia Awards took take place on Thursday, April 4 at the Vancouver Convention Centre with several hundred guests representing the British Columbia life sciences community.

"We are honored to be recognized by our industry peers in this way," commented Simon Pimstone, Xenon's President and CEO. "This is the beginning of a very exciting year for Xenon. We've worked diligently and deliberately to create strong partnerships with top tier pharmaceutical companies and to develop a deep and diverse pipeline of products. One of Xenon's early technologies is now in an approved product to treat lipoprotein lipase deficiency, we have a late stage clinical program initiating for our novel pain medicine and an early development stage product for the treatment of anemia. We look forward to an exciting year at Xenon as our products advance on the market and in the clinic."

About Xenon Pharmaceuticals Inc. Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

For more information regarding this press release, contact: Dr. Robin Sherrington, SVP Business & Corporate Development (604) 484-3300, ddunn@xenon-pharma.com

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

SOURCE Xenon Pharmaceuticals Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES